Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

786
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
786
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

521
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
521

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction.

Biotechnology and bioengineering·2026
Same author

Trade-off analysis between soil organic carbon and maize yield under no-tillage: implication for sustainable cropland management.

Journal of environmental management·2026
Same author

Rapid Recognition of Carfilzomib-Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients.

Chronic diseases and translational medicine·2026
Same author

<i>Alfaria yunnanensis</i> sp. nov., a novel myrothecium-like species isolated from <i>Oryza sativa</i> in Yunnan, China.

International journal of systematic and evolutionary microbiology·2026
Same author

Use of Wearable Devices to Augment Traditional Measurements of Postoperative Outcomes Following Total Joint Arthroplasty: Systematic Review.

JMIR rehabilitation and assistive technologies·2026
Same author

Rayleigh-Brillouin hybrid distributed acoustic sensing for high-sensitivity ultra-low frequency detection.

Optics letters·2026

Related Experiment Video

Updated: Jan 2, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling

Ying Luo1, Pijian Yang1, Zhengming Li2

  • 1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People's Republic of China.

Drug Design, Development and Therapy
|December 11, 2019
PubMed
Summary

Liraglutide treatment improved lipid metabolism and reduced inflammation in mice with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). This suggests liraglutide as a potential therapy for NAFLD progression.

Keywords:
inflammatory signaling pathwayliraglutidenonalcoholic fatty liver disease

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.3K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K

Related Experiment Videos

Last Updated: Jan 2, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.3K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K

Area of Science:

  • Metabolic disease research
  • Inflammation and immunology
  • Hepatology

Background:

  • Chronic metabolic diseases like obesity and type 2 diabetes (T2DM) are linked to low-grade tissue inflammation.
  • Non-alcoholic fatty liver disease (NAFLD) prevalence is high in T2DM patients due to inflammation's role.
  • Investigating liraglutide's potential to treat NAFLD by modulating inflammatory pathways.

Purpose of the Study:

  • To investigate liraglutide's effect on lipid metabolism disorders in NAFLD.
  • To assess liraglutide's ability to prevent NAFLD progression via inflammatory pathway modulation.
  • To explore new therapeutic options for NAFLD.

Main Methods:

  • A 2x2 factorial analysis experiment was conducted.
  • A mouse model of NAFLD with T2DM was induced using a high-fat diet (HFD).
  • Mice were treated with liraglutide for 10 weeks; liver tissues were analyzed for lipid accumulation and inflammatory markers (α-SMA, IL-1β, TNF-α, NF-κB, IκB) using histological staining, RT-PCR, and Western blotting.

Main Results:

  • Liraglutide reduced body weight and fasting blood glucose in HFD-fed mice.
  • Liraglutide treatment decreased elevated mRNA and protein levels of α-SMA, IL-1β, TNF-α, and NF-κB in the liver.
  • Liraglutide upregulated the expression of the NF-κB inhibitory protein IκB.

Conclusions:

  • Liraglutide significantly improves hepatic steatosis in NAFLD mice.
  • The therapeutic effect is primarily achieved by downregulating inflammatory signaling mediators in the TNF-α pathway.
  • Liraglutide demonstrates potential as a treatment for NAFLD associated with T2DM.